Research Paper Volume 16, Issue 3 pp 2320—2339

Comprehensive analysis of ALG3 in pan-cancer and validation of ALG3 as an onco-immunological biomarker in breast cancer

class="figure-viewer-img"

Figure 5. Association with ALG3 and clinico-pathological characters, prognostic value in breast cancer. (A) Expression levels of ALG3 were indicated in normal breast tissues and different sub-type of breast cancer tissues. (B) Association between expression level of ALG3 and TP53 mutant status was demonstrated. (C) The association between expression immune subtypes and expression level of ALG3. C1 (wound healing); C2 (IFN-gamma dominant); C3 (inflammatory); C4 (lymphocyte depleted); C5 (immunologically quiet); C6 (TGF-β dominant). (D) TCGA database revealed that high expression level of ALG3 in breast cancer patients predicated poorer OS and DFS rates. (E) The GEO databases revealed that high expression level of ALG3 in breast cancer patients predicated poorer OS and DFS rates. (F, G) ROC analysis for prediction of ALG3 for OS and DFS, respectively.